Skip to content
10-Q

Quarterly Report

First Tracks Biotherapeutics, Inc. TRAX

0001193125-26-224190

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 34.89M sh
Capex Q1 2026 · Mar 31, 2026 $17K
Capex Q1 2026 · Mar 31, 2025 $35K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$32.56M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$45.01M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $248.47M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $238.2M
Stockholders Equity Q1 2026 · Mar 31, 2026 $257.46M
Stockholders Equity Q1 2026 · Dec 31, 2025 $287.49M
Stockholders Equity Q1 2026 · Mar 31, 2025 $357.72M
Stockholders Equity Q1 2026 · Dec 31, 2024 $391.6M
Current Liabilities Q1 2026 · Mar 31, 2026 $33.11M
Current Liabilities Q1 2026 · Dec 31, 2025 $31.02M
Current Assets Q1 2026 · Mar 31, 2026 $289.4M
Current Assets Q1 2026 · Dec 31, 2025 $316.4M
Total Assets Q1 2026 · Mar 31, 2026 $290.58M
Total Assets Q1 2026 · Dec 31, 2025 $330.55M
Sga Expense Q1 2026 · Mar 31, 2026 $18.86M
Sga Expense Q1 2026 · Mar 31, 2025 $9.82M
Rd Expense Q1 2026 · Mar 31, 2026 $33.96M
Rd Expense Q1 2026 · Mar 31, 2025 $41.47M
Net Income Q1 2026 · Mar 31, 2026 −$50.48M
Net Income Q1 2026 · Mar 31, 2025 −$47.2M
Operating Income Q1 2026 · Mar 31, 2026 −$52.81M
Operating Income Q1 2026 · Mar 31, 2025 −$51.28M